# Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta

> **NCT01745185** · — · COMPLETED · sponsor: **O & O Alpan LLC** · enrollment: 30 (estimated)

## Conditions studied

- Fabry Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01745185
- **Lead sponsor:** O & O Alpan LLC
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-04-07
- **Final completion:** 2016-08-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01745185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01745185, "Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01745185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*